Net revenue surged by 6.1% on an operational basis during the quarter.
The GAAP diluted earnings per share (EPS) for the quarter ended 30 June grew by 21.4% to 0.51 from $0.42 in Q2 2021.
An 11.2% surge in adjusted diluted EPS of $3.37 was reported in Q2 this year against $3.03 in the prior-year quarter.
The immunology portfolio of the company delivered global net revenues of $7.21bn in this quarter, representing a surge of 17.8% on a reported basis and 19.2% on an operational basis.
AbbVie ’s Humira (adalimumab) generated a 9.6% rise in net revenues to $4.7bn in the US.
During the quarter, the company’s Skyrizi and Rinvoq generated combined global net revenues of $1.84bn.
The hematologic oncology and neuroscience portfolios delivered $1.65bn and $1.66bn in global net revenues, showing a decline of 9.1% and growth of 13.7%, respectively, on a reported basis.
Global net revenues generated by the aesthetics portfolio saw a 4.4% decline on a reported basis to $1.37bn.
AbbVie chairman and CEO Richard Gonzalez said: “We delivered another strong quarter with substantial progress for our new products and indications.
“Importantly, Skyrizi and Rinvoq continued their impressive ramps and are on pace to deliver approximately $7.5bn in combined annual sales, underscoring their significant potential.
“The momentum of our business, combined with advances across our pipeline, continue to support AbbVie’s promising long-term outlook.”
For the full-year 2022, the company has provided an adjusted diluted EPS guidance range of $13.78 to $13.98.
In February, AbbVie reported net revenues of nearly $56.2bn for the full year 2021 on a GAAP basis.